Teva Pharmaceuticals USA v. Sandoz — Supreme Court Sets Appellate Review Standard for Patent Claim Construction

Background

Teva Pharmaceuticals holds patents covering Copaxone, a blockbuster drug used to treat multiple sclerosis. When Sandoz sought FDA approval to sell a generic version, Teva sued for patent infringement. The central dispute in court was how to interpret — or “construe” — the meaning of certain patent claims. Claim construction is the process by which a judge defines the scope of a patent’s protection, and it is often the most important step in a patent case: the broader the construction, the more infringers are caught; the narrower, the fewer.

The district court construed the claims in Teva’s favor after hearing expert testimony about technical terms. On appeal, the Federal Circuit reviewed the lower court’s construction without any deference — that is, it looked at the question completely fresh, as if the district court had never ruled. The Federal Circuit reversed, and Teva petitioned the Supreme Court to clarify what standard of review applies when an appellate court reviews a district court’s claim construction rulings.

The Court’s Holding

Justice Breyer, writing for a seven-Justice majority, held that Federal Rule of Civil Procedure 52(a)(6) — which requires appellate courts to accept a trial court’s factual findings unless “clearly erroneous” — applies to claim construction. This means that when a district court makes subsidiary factual findings as part of construing a patent (for example, findings about what a technical term meant to engineers in a given field), the Federal Circuit cannot simply substitute its own view. It must show that the district court was clearly wrong before overturning that factual finding.

The Court drew a distinction between two types of determinations: (1) subsidiary factual findings — things like what a person skilled in the art would have understood a term to mean, often established through expert testimony — which are reviewed for clear error; and (2) the ultimate legal conclusion about claim scope, which remains reviewed de novo (fresh). In practice, this means the Federal Circuit must give more deference to district courts when those courts have relied on extrinsic evidence such as expert witnesses or technical dictionaries.

Key Takeaways

• Appellate review of patent claim construction is now a two-step process: factual underpinnings get clear-error review; the ultimate legal conclusion gets de novo review.
• District courts that hold evidentiary hearings and hear expert testimony on claim construction issues have their factual findings protected from easy reversal on appeal.
• The ruling reduces (but does not eliminate) the Federal Circuit’s historically high reversal rate on claim construction, which had created uncertainty for patent holders and challengers alike.
• Litigants who want to lock in favorable claim construction findings should present thorough expert and extrinsic evidence at the district court level.

Why It Matters

Before this decision, the Federal Circuit reviewed all aspects of claim construction de novo, making it one of the most frequently reversed issues in patent law. Studies showed the Federal Circuit reversed claim constructions at a rate exceeding 30 percent — far higher than other issues — creating enormous uncertainty for companies deciding whether to litigate, settle, or license a patent dispute. By requiring deference to factual findings, the Supreme Court aimed to stabilize patent law and make district court judgments more durable.

For technology companies and pharmaceutical firms, this ruling means that winning on claim construction at the trial level is now a more durable victory. It also encourages parties to invest in thorough evidentiary records at the district court level rather than treating trial as merely a warm-up for an appeal.